ClinVar Genomic variation as it relates to human health
NM_000540.3(RYR1):c.14818G>A (p.Ala4940Thr)
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_000540.3(RYR1):c.14818G>A (p.Ala4940Thr)
Variation ID: 65927 Accession: VCV000065927.51
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 19q13.2 19: 38585952 (GRCh38) [ NCBI UCSC ] 19: 39076592 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Oct 1, 2013 Oct 20, 2024 Apr 6, 2023 - HGVS
-
Nucleotide Protein Molecular
consequenceNM_000540.3:c.14818G>A MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_000531.2:p.Ala4940Thr missense NM_001042723.2:c.14803G>A NP_001036188.1:p.Ala4935Thr missense NC_000019.10:g.38585952G>A NC_000019.9:g.39076592G>A NG_008866.1:g.157253G>A LRG_766:g.157253G>A LRG_766t1:c.14818G>A LRG_766p1:p.Ala4940Thr P21817:p.Ala4940Thr - Protein change
- A4940T, A4935T
- Other names
-
NM_000540.2(RYR1):c.14818G>A
- Canonical SPDI
- NC_000019.10:38585951:G:A
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
- -
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
-
Trans-Omics for Precision Medicine (TOPMed) 0.00000
Exome Aggregation Consortium (ExAC) 0.00001
The Genome Aggregation Database (gnomAD) 0.00001
- Links
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
RYR1 | No evidence available | No evidence available |
GRCh38 GRCh37 |
8921 | 9236 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Pathogenic (1) |
no assertion criteria provided
|
May 11, 2010 | RCV000056174.4 | |
Pathogenic/Likely pathogenic (8) |
criteria provided, multiple submitters, no conflicts
|
Mar 8, 2023 | RCV000119566.45 | |
Pathogenic (2) |
criteria provided, multiple submitters, no conflicts
|
Dec 10, 2023 | RCV000529075.13 | |
Uncertain significance (1) |
reviewed by expert panel
|
Apr 6, 2023 | RCV001588883.4 | |
Likely pathogenic (1) |
criteria provided, single submitter
|
Jun 11, 2020 | RCV004017358.1 | |
See cases
|
Uncertain significance (1) |
criteria provided, single submitter
|
Mar 8, 2022 | RCV004584343.1 |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Uncertain significance
(Apr 06, 2023)
|
reviewed by expert panel
Method: curation
|
Malignant hyperthermia, susceptibility to, 1
(Autosomal dominant inheritance)
Affected status: unknown
Allele origin:
germline
|
ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel, ClinGen
FDA Recognized Database
Study: ClinGen Accession: SCV001816183.2 First in ClinVar: Sep 08, 2021 Last updated: Apr 23, 2023 |
Comment:
This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies … (more)
This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of alanine with threonine at codon 4940 of the RYR1 protein, p.(Ala4940Thr). This variant was not present in a large population database (gnomAD) at the time this variant was interpreted. This variant has been identified in two unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, both of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Moderate (PMID:15731587, personal communication from VCEP laboratory). No functional studies were identified for this variant. This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1_Sup (PMID: 21118704). A REVEL score >0.85 (0.882) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as a Variant of Unknown Significance. Criteria implemented: PS4_Moderate, PM1_Supporting, PP3_Moderate. (less)
|
|
Pathogenic
(Mar 27, 2013)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
(Autosomal unknown)
Affected status: yes
Allele origin:
germline
|
Genetic Services Laboratory, University of Chicago
Accession: SCV000194811.1
First in ClinVar: Nov 23, 2014 Last updated: Nov 23, 2014 |
|
|
Pathogenic
(Mar 22, 2018)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
PreventionGenetics, part of Exact Sciences
Accession: SCV000852464.1
First in ClinVar: Dec 10, 2016 Last updated: Dec 10, 2016 |
|
|
Pathogenic
(-)
|
criteria provided, single submitter
Method: clinical testing
|
RYR1-related disorder
Affected status: yes
Allele origin:
germline
|
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego
Accession: SCV004046076.1
First in ClinVar: Oct 21, 2023 Last updated: Oct 21, 2023 |
Comment:
This variant has been previously reported as a heterozygous change in patients with Central Core Disease (MIM: #117000; PMID: 32403337, 31321302, 30155738, 14670767), and as … (more)
This variant has been previously reported as a heterozygous change in patients with Central Core Disease (MIM: #117000; PMID: 32403337, 31321302, 30155738, 14670767), and as a compound heterozygous change in patients with congenital myopathy (PMID: 30155738, 31395954). Functional studies in cells have shown that the c.14818G>A (p.Ala4940Thr) variant significantly reduces the threshold for spontaneous Ca2+ release during store Ca2+ overload (SOICR), which causes uncontrolled muscle contraction (PMID: 28687594). It is absent from the gnomAD population database and thus is presumed to be rare. The c.14818G>A (p.Ala4940Thr) variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.14818G>A (p.Ala4940Thr) variant is classified as Pathogenic. (less)
|
|
Pathogenic
(Mar 08, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Revvity Omics, Revvity
Accession: SCV002019952.3
First in ClinVar: Nov 29, 2021 Last updated: Feb 04, 2024 |
|
|
Pathogenic
(Dec 10, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
RYR1-related disorder
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV000659859.9
First in ClinVar: Dec 26, 2017 Last updated: Feb 28, 2024 |
Comment:
This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 4940 of the RYR1 protein (p.Ala4940Thr). … (more)
This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 4940 of the RYR1 protein (p.Ala4940Thr). This variant is present in population databases (rs118192158, gnomAD 0.0009%). This missense change has been observed in individuals with autosomal dominant central core disease (PMID: 1256913, 12467748, 14670767, 15731587, 23183335, 23558838). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 65927). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on RYR1 protein function. For these reasons, this variant has been classified as Pathogenic. (less)
|
|
Likely Pathogenic
(Jun 11, 2020)
|
criteria provided, single submitter
Method: clinical testing
|
Malignant hyperthermia of anesthesia
Affected status: unknown
Allele origin:
germline
|
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Accession: SCV004848373.1
First in ClinVar: Apr 20, 2024 Last updated: Apr 20, 2024 |
Comment:
The p.Ala4940Thr variant in RYR1 has been previously reported in at least 5 heterozygous individuals with central core disease or RYR1-related myopathy, and segregated in … (more)
The p.Ala4940Thr variant in RYR1 has been previously reported in at least 5 heterozygous individuals with central core disease or RYR1-related myopathy, and segregated in 5 affected relatives (Kraeva 2013 PMID 23183335, Todd 2018 PMID 30155738, Kushnir 2020 PMID 32236737, Davis 2003 PMID 12565913, Quinlivan 2003 PMID 14670767). It has also been reported in at least 1 individual with malignant hyperthermia (MH) susceptibility (Brandom 2013 PMID 23558838, Sambuughin PMID 15731587) and in 1 compound heterozygous individual with myopathy (Todd 2018 PMID 30155738). This variant was absent from large population studies, but has been reported in ClinVar (Variation ID 65927). In vitro evidence in transfected HEK293 cells indicates that this variant affects protien function (Chen 2017 PMID 28687594). In addition, a transgenic C. elegan model with the Ala4940Thr variant showed increased sensitivity to halothane and caffeine and decreased locomotion (Baines 2017 PMID 28325813). Lastly, in a study performed in muscle tissue from patients carrying the Ala4940Thr variant, RYR1 was co-immunoprecipitated with calstabin1, which binds to RYR1 and stabilizes the closed state of the calcium channel. Reduced RYR1-calstabin1 was observed relative to controls, which suggests that the variant results in a leaky RYR1 calcium channel (Kushnir 2020 PMID 32236737). Computational prediction tools and conservation analyses suggest an impact to the protein. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant central core disease but has also been reported in MH susceptibility. ACMG/AMP criteria applied: PM2, PS4_Moderate, PP1_Moderate, PP3, PS3_Moderate. (less)
|
|
Uncertain significance
(Mar 08, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
see cases
Affected status: yes
Allele origin:
unknown
|
Institute of Human Genetics, University Hospital Muenster
Accession: SCV002499665.2
First in ClinVar: Apr 23, 2022 Last updated: Jul 07, 2024 |
Comment:
ACMG categories: PM1,PM2,PP3
Number of individuals with the variant: 1
Clinical Features:
Myopathy (present)
Age: 0-9 years
Sex: female
Tissue: blood
|
|
Likely pathogenic
(Aug 31, 2017)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Eurofins Ntd Llc (ga)
Accession: SCV000225118.5
First in ClinVar: Jun 29, 2015 Last updated: Dec 10, 2016 |
Number of individuals with the variant: 5
Sex: mixed
|
|
Pathogenic
(Jun 03, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Not provided
Affected status: unknown
Allele origin:
germline
|
Mayo Clinic Laboratories, Mayo Clinic
Accession: SCV001715524.1
First in ClinVar: Jun 15, 2021 Last updated: Jun 15, 2021 |
Comment:
PS3, PS4_M, PM1, PM2, PP1, PP3, PP4
Number of individuals with the variant: 1
|
|
Pathogenic
(Mar 12, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Not Provided
Affected status: yes
Allele origin:
germline
|
GeneDx
Accession: SCV000329509.9
First in ClinVar: Dec 06, 2016 Last updated: Mar 04, 2023 |
Comment:
Also reported in a patient with malignant hyperthermia susceptibility (Sambuughin et al., 2005); Published functional studies using transgenic C. elegans with the A4940T variant demonstrate … (more)
Also reported in a patient with malignant hyperthermia susceptibility (Sambuughin et al., 2005); Published functional studies using transgenic C. elegans with the A4940T variant demonstrate a damaging effect of increased sensitivity to halothane and caffeine, with decreased locomotion (Nicoll Baines et al., 2017); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 14670767, 23558838, 12565913, 20301565, 15731587, 12467748, 28325813, 25747005, 23183335, 28687594, 16084090, 1256913, 31321302, 31395954, 31559918, 32403337, 33646171) (less)
|
|
Pathogenic
(Nov 01, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
CeGaT Center for Human Genetics Tuebingen
Accession: SCV001961815.20
First in ClinVar: Oct 08, 2021 Last updated: Oct 20, 2024 |
Number of individuals with the variant: 2
|
|
pathologic
(May 11, 2010)
|
no assertion criteria provided
Method: curation
|
Central Core Disease
Affected status: not provided
Allele origin:
not provided
|
GeneReviews
Accession: SCV000087262.1
First in ClinVar: Oct 01, 2013 Last updated: Oct 01, 2013 |
Comment:
Converted during submission to Pathogenic.
|
|
not provided
(-)
|
no classification provided
Method: not provided
|
not provided
Affected status: not provided
Allele origin:
unknown
|
Leiden Muscular Dystrophy (RYR1)
Accession: SCV000154473.1
First in ClinVar: Jun 09, 2014 Last updated: Jun 09, 2014 |
|
|
click to load more click to collapse |
Germline Functional Evidence
There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Intracellular calcium leak as a therapeutic target for RYR1-related myopathies. | Kushnir A | Acta neuropathologica | 2020 | PMID: 32236737 |
Infant mortality: the contribution of genetic disorders. | Wojcik MH | Journal of perinatology : official journal of the California Perinatal Association | 2019 | PMID: 31395954 |
Congenital myopathies in the adult neuromuscular clinic: Diagnostic challenges and pitfalls. | Nicolau S | Neurology. Genetics | 2019 | PMID: 31321302 |
Correlation of phenotype with genotype and protein structure in RYR1-related disorders. | Todd JJ | Journal of neurology | 2018 | PMID: 30155738 |
Parental mosaicism in RYR1-related Central Core Disease. | Marks S | Neuromuscular disorders : NMD | 2018 | PMID: 29576327 |
Reduced threshold for store overload-induced Ca(2+) release is a common defect of RyR1 mutations associated with malignant hyperthermia and central core disease. | Chen W | The Biochemical journal | 2017 | PMID: 28687594 |
Aging Effects of Caenorhabditis elegans Ryanodine Receptor Variants Corresponding to Human Myopathic Mutations. | Nicoll Baines K | G3 (Bethesda, Md.) | 2017 | PMID: 28325813 |
Compound RYR1 heterozygosity resulting in a complex phenotype of malignant hyperthermia susceptibility and a core myopathy. | Kraeva N | Neuromuscular disorders : NMD | 2015 | PMID: 25958340 |
A novel large deletion in the RYR1 gene in a Belgian family with late-onset and recessive core myopathy. | Remiche G | Neuromuscular disorders : NMD | 2015 | PMID: 25747005 |
Abstracts of the 33rd Annual Meeting of the European Malignant Hyperthermia Group (EMHG), May15-17, 2014, Würzburg, Germany. | Krivosic-Horber R | BMC anesthesiology | 2014 | PMID: 25749300 |
Central Core Disease – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY. | Adam MP | - | 2014 | PMID: 20301565 |
Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States. | Brandom BW | Anesthesia and analgesia | 2013 | PMID: 23558838 |
Novel excitation-contraction uncoupled RYR1 mutations in patients with central core disease. | Kraeva N | Neuromuscular disorders : NMD | 2013 | PMID: 23183335 |
Mutations in RYR1 in malignant hyperthermia and central core disease. | Robinson R | Human mutation | 2006 | PMID: 16917943 |
Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders. | Treves S | Neuromuscular disorders : NMD | 2005 | PMID: 16084090 |
Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population. | Sambuughin N | Anesthesiology | 2005 | PMID: 15731587 |
Central core disease: clinical, pathological, and genetic features. | Quinlivan RM | Archives of disease in childhood | 2003 | PMID: 14670767 |
Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene. | Davis MR | Neuromuscular disorders : NMD | 2003 | PMID: 12565913 |
The spectrum of pathology in central core disease. | Sewry CA | Neuromuscular disorders : NMD | 2002 | PMID: 12467748 |
Immunity to Hymenolepis diminuta: unresponsiveness of the athymic nude mouse to infection. | Bland PW | Parasitology | 1976 | PMID: 1256913 |
http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=RYR1 | - | - | - | - |
https://erepo.clinicalgenome.org/evrepo/ui/interpretation/9eaf27f2-ff5e-4590-907b-4854aba6ad85 | - | - | - | - |
click to load more click to collapse |
Text-mined citations for rs118192158 ...
HelpRecord last updated Nov 03, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.